InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 319 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among... July 18, 2024 Pattern of DNA Damage Links Colorectal Cancer and Diet High in... July 22, 2021 The rise of the ‘long-waiter’ – why cancer waiting times are... November 10, 2022 Load more HOT NEWS Mouse Study Points to Strategy for Preserving Bone During Chemotherapy Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection...
